TY - JOUR
T1 - Concepts in immuno-oncology
T2 - tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
AU - Viardot, Andreas
AU - Locatelli, Franco
AU - Stieglmaier, Julia
AU - Zaman, Faraz
AU - Jabbour, Elias
N1 - Funding Information:
AV receives consulting fees from Amgen, Roche, Kite/Gilead, and Novartis and has worked with Janssen. FL received honoraria from Amgen for participating in advisory boards and for a speakers’ bureau. EJ receives research grants and consults for Amgen, AbbVie, Adaptive Biotechnologies, Bristol-Myers Squibb, Pfizer, and Takeda. JS and FZ are employees and stockholders of Amgen Inc.
Funding Information:
The authors wish to thank Lesley Blogg, PhD, and Anjali Reddy of Fishawack Communications Inc. for medical writing assistance in the preparation of this manuscript, which was funded by Amgen Inc.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/10/1
Y1 - 2020/10/1
N2 - The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.
AB - The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.
KW - Acute lymphoblastic leukemia
KW - B cell malignancies
KW - Bispecific T cell engager
KW - BiTE molecule
KW - Blinatumomab
KW - CD19
KW - Non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85089908159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089908159&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04221-0
DO - 10.1007/s00277-020-04221-0
M3 - Review article
C2 - 32856140
AN - SCOPUS:85089908159
VL - 99
SP - 2215
EP - 2229
JO - Ann. Hematol.
JF - Ann. Hematol.
SN - 0939-5555
IS - 10
ER -